Cub Foods addresses gluten allergies with diet management program
STILLWATER, Minn. Supervalu’s Cub Foods is looking to help customers with gluten sensitivity with the launch of a new, informative diet management program at its stores located in Minnesota, Illinois and Wisconsin.
Developed by Supervalu’s health-and-wellness team and dietitians, the program will roll out in phases over the next three months. The program will present in-store signage about gluten-free foods in Cub Foods stores — as well as in Supervalu’s family of other stores — and also will feature gluten-free shopping lists and guides. In addition to recipes, more extensive gluten-free shopping lists and snack and meal solutions will be available on the stores’ websites.
The new program builds on Supervalu’s Nutrition iQ program, an in-store nutrition ratings system to help customers identify healthy food choices.
“For people suffering from gluten intolerance, eating foods with gluten causes inflammation and damage to the lining of the small intestine, which can result in nutrients passing through the body without being absorbed. This may contribute to other health concerns, including malnutrition, some types of cancers and a variety of autoimmune diseases,” said Anthony Provenzano, Supervalu pharmacy director of clinical programs. “As a whole, the U.S. population is seeing an uptick in gluten intolerance, and there are many more people who have it — but don’t know it. This program is designed to help people manage a gluten-free diet and hopefully encourage others to seek advice from a healthcare professional about a possible sensitivity to gluten.”
Actavis gets FDA approval for generic Cozaar
MORRISTOWN, N.J. Actavis has received regulatory approval from the Food and Drug Administration for its high blood pressure drug.
The drug maker said its losartan potassium tablets, USP, will be available in 25-mg, 50-mg and 100-mg strengths. The drug is a generic version of Merck’s Cozaar.
Losartan potassium tablets, USP, had sales of approximately $940 million for the 12 months ended June 30, according to IMS Health.
Express Scripts looks to curb nonadherence among patients
ST. LOUIS Pharmacy benefit manager Express Scripts said it has created a way to accurately predict which patients were most at risk of not adhering to their medications.
The PBM announced Monday that it had created a computer model that could predict whether a patient would fail to take medications as prescribed up to a year in advance, allowing early intervention to improve adherence. The company said patent protection for the model is pending. According to Express Scripts’ 2009 Drug Trend Report, nonadherence results in $106 billion being wasted on increased medical costs every year.
“The problem of nonadherence isn’t new — it’s easy to walk through a hospital and identify people who would not be there if they had simply taken their medications,” Express Scripts chief medical officer Steven Miller said. “But our new predictive models allow us to do something that wasn’t possible before: better identify those patients before they run into trouble and tailor practical, patient-centric solutions that target the specific factors that put them at risk for nonadherence.”